The disruptive intelligence toolkit
for the oncology universe.

Real-time KOL and trial intelligence from verified oncologists. No bots. No vendor noise. Every insight sourced, cited, and audited.

For medical affairs, insights, and med comms teams — free for oncologists.

500+ verified US oncologists 50+ trial profiles 10M+ impressions analyzed ASCO 2025 live coverage
Lung
EGFR, ALK, KRAS
Breast
HER2+, HR+, TNBC
Myeloma
NDMM, RRMM
GI
CRC, HCC, Gastric
GU
Bladder, RCC, Prostate
Brian Shields

Army veteran. Digital health entrepreneur. Oncology whistleblower. Brian Shields built KOL Pulse because oncology intelligence should be transparent, audited, and accessible — not locked behind $500K enterprise contracts. As one of a few oncology whistleblowers, he knows firsthand why transparency in physician-industry relationships matters. Every feature reflects this mission.

Featured Clinical Trials · 120+ profiles

AI-generated trial intelligence — with real slides and real KOL commentary

Each profile includes KOL photos, conference slides with OCR, verbatim sentiment, engagement leaderboards, and clinical narrative verified against FDA press releases and pivotal publications.

New Fresh from ASCO GI 2026 + ASCO GU 2026 8 new trial profiles live
Browse all 120+ trial profiles with filters →
Featured KOL Insights

What oncologists are saying — verbatim, audited, in context

Real quotes from real physicians. Positive and critical sentiment captured across clinical trials and conferences. Every quote links to the original post.

Noemi Reguart
Noemi Reguart
Thoracic Oncology, Barcelona
@NReguart
Lung Cancer
Osimertinib BEATEN!! MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, p<0.005, 3yr 60% vs 51%) and landmark 3-yr icPFS improvement (36% vs 18%) — first combo to show OS superiority over SoC
MARIPOSA Trial POSITIVE
Paolo Tarantino
Paolo Tarantino, MD
Breast Oncology, Dana-Farber
@PTarantinoMD
Breast Cancer
ADCs are rapidly moving to earlier line treatment for breast cancer. Will likely reach the (neo)adjuvant setting soon. Here's a recap of key ADC phase 3 trials expected to shape practice
DESTINY-Breast09 POSITIVE
Vincent Rajkumar
Vincent Rajkumar, MD
Multiple Myeloma, Mayo Clinic
@VincentRK
Multiple Myeloma
A simplified algorithm of frontline therapy today. Big changes. Thanks @Dr_AmerZeidan for inviting me to present on current treatment of myeloma at the New England Hematologic Malignancies Symposium.
PERSEUS Trial POSITIVE
Nicholas Hornstein
Nicholas Hornstein
GI Medical Oncology, Houston
@GIMedOnc
GI Cancer
#ASCO2025 BREAKWATER OS data lands — and it must redefine 1L standard of care in BRAF V600E-mutant mCRC. EC + mFOLFOX6 vs SOC: PFS: 12.8 vs 7.1 mo (HR 0.53, p < 0.0001)
BREAKWATER Trial POSITIVE
d.planchard
David Planchard, MD PhD
Thoracic Oncology, Institut Gustave Roussy
@dplanchard
Lung Cancer
FLAURA2 regimen raises the bar! New data from a China study shows impressive PFS/OS gains for Osi + Chemo in EGFRm + TP53 co-mutated pts. Confirms 1L SOC status across the board
FLAURA2 Trial POSITIVE
Hope Rugo
Hope Rugo, MD
Breast Oncology, UCSF
@hoperugo
Breast Cancer
#SABCS2025 Honored to present this exciting data. Efficacy seen regardless of mESR1 or mPIK3CA with ela+eve. EVERA also shows benefit with giredestrant/EVE across mESR1 as did EMBER3.
EMBER-3 Trial POSITIVE
Tom Powles
Tom Powles, MD
GU Oncology, Barts Cancer Institute
@tompowles1
GU Cancer
Enfortumab Vedotin + pembro shows broad spectrum of activity for RR PFS and OS in all subgroups. This includes lymph node disease, liver mets, PD-L1 status, upper tract disease, platinum eligibility. This +ve data underlines EVP as a new standard of care
EV-302 Trial POSITIVE
Elizabeth Plimack
Elizabeth Plimack, MD
GU Oncology, Fox Chase Cancer Center
@ERPlimackMD
GU Cancer
NIAGARA presented #ESMO24 and published today @NEJM — huge accomplishment, 1000+ patients enrolled. Exciting results! Some thoughts on applying them to practice in perioperative muscle-invasive bladder cancer.
NIAGARA Trial POSITIVE
Neeraj Agarwal
Neeraj Agarwal, MD, FASCO
GU Oncology, Huntsman Cancer Institute
@neerajaiims
GU Cancer
Congrats @shilpaonc for oral ab#4502 @ASCO #ASCO25. In the Ph3 EV-302 trial in mUC #bladdercancer, pts achieving a CR had higher PFS & OS w/ EV+P vs. chemo (exploratory analysis).
EV-302 Trial POSITIVE
View all 500+ oncology KOL insights →
Conference Intelligence

Real-time KOL tracking from major oncology conferences

Influencer networks, social engagement maps, and KOL sentiment — built live from conference data.

See all 9 conferences covered (AACR, ASCO, ESMO, ASH, SABCS…) →
ELCC 2026 Trial Networks

Interactive KOL social networks for ELCC26 trials

D3.js network visualizations showing retweet patterns, mention clusters, and influence mapping from oncologists discussing these trials at ELCC 2026.

Live Network Graphs

See who's talking to whom

Each node is a verified oncologist. Each edge is a retweet, quote, or mention. Hover any trial below to explore the live graph.

Live KOL Feed — AACR 2026

This is real. Right now. Live from #AACR26 in San Diego.

Top oncology KOLs reacting to AACR 2026 abstracts — verbatim quotes, engagement metrics, sentiment, and direct links to every post.

See full AACR 2026 coverage →
Influencer Networks

See who actually drove the AACR 2026 conversation.

2,517 accounts classified · 303 verified US physicians across 36 states · 244 non-US physicians across 37 countries · interactive retweet graph with 680 nodes and 1,711 edges. Click any KOL to filter the network to their direct connections.

AACR 2026 Influencer Networks — Top KOL Voices
Live · AACR 2026

Interactive KOL Network & U.S. Heat Map

  • 📊 Top KOL Voices leaderboard with state, institution, topics
  • 🗺️ U.S. heat map · click any state for verified physicians
  • 🌍 37 countries · click for non-US physicians by country
  • 🕸️ Force-directed retweet graph · filter by Top 10 KOLs
  • 📈 Engagement table with topics, trials, and impressions
View Live Page → kolpulse.com/aacr26-influencer-networks
2,517
Accounts classified
303
US physicians (36 states)
37
Countries represented
680
Network nodes / 1,711 edges
What Makes KOL Pulse Different

What does "AI-Native" actually mean?

Most KOL tools are built for humans to click through dashboards. KOL Pulse is different. Our intelligence is structured so that both humans AND AI systems can use it — meaning you can browse our website, embed our widgets, or query our data from inside Claude, NotebookLM, or Perplexity.

No portal to log into. No dashboard to learn. Intelligence goes where you already work.

Audited Data No Hallucinations Full Provenance Public Sources Only
What you want to doHow
Browse trial & KOL intelligenceOn this website — free, no login
Ask questions about any KOL or trialQuery via Claude with our MCP server
Feed intelligence into your AI toolsAdd our pages to NotebookLM, Perplexity, etc.
Build custom analysis workflowsAPI, Lambda functions, Claude skills
Enterprise deploymentPrivate instance, white-label, dedicated support

See the intelligence for yourself.

Browse trial profiles, explore conference networks, or tell us what you need.

See a Trial Profile Explore ELCC26 Networks Book a Walkthrough